Trial Profile
Phase II study of Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy for maintenance of Patients With Neovascular Maculopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; VEGFR-1 peptide vaccine; VEGFR-2 peptide vaccine
- Indications Age-related macular degeneration; Retinal degeneration
- Focus Therapeutic Use
- 08 May 2017 Status changed from recruiting to completed.
- 22 Sep 2011 New trial record